{
    "ticker": "GMAB",
    "name": "Genmab A/S",
    "description": "Genmab A/S is a biotechnology company specializing in the development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has established itself as a leader in the field of immunotherapy, aiming to improve the lives of patients with cancer through innovative treatment options. The company is known for its proprietary technologies and a robust pipeline of monoclonal antibodies, including its flagship product, Darzalex (daratumumab), which is used in the treatment of multiple myeloma. Genmab collaborates with various pharmaceutical companies to bring new therapies to market, leveraging its expertise in antibody engineering and development. The company\u2019s research efforts are focused on creating next-generation antibody-based therapies that can provide better efficacy and safety profiles compared to existing treatments. With a strong commitment to scientific innovation and patient-centric solutions, Genmab strives to make a meaningful impact in oncology and beyond.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Copenhagen, Denmark",
    "founded": "1999",
    "website": "https://www.genmab.com",
    "ceo": "Jan van de Winkel",
    "social_media": {
        "twitter": "https://twitter.com/genmab",
        "linkedin": "https://www.linkedin.com/company/genmab/"
    },
    "investor_relations": "https://www.genmab.com/investors",
    "key_executives": [
        {
            "name": "Jan van de Winkel",
            "position": "CEO"
        },
        {
            "name": "Anthony Pagano",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Antibody Therapeutics",
            "products": [
                "Darzalex",
                "Teprotumumab",
                "DuoBody"
            ]
        }
    ],
    "seo": {
        "meta_title": "Genmab A/S | Innovating Antibody Therapeutics for Cancer",
        "meta_description": "Genmab A/S is a biotechnology pioneer focused on developing differentiated antibody therapeutics for cancer treatment. Explore our innovative pipeline and commitment to patient care.",
        "keywords": [
            "Genmab",
            "Biotechnology",
            "Cancer Treatment",
            "Antibody Therapeutics",
            "Darzalex"
        ]
    },
    "faq": [
        {
            "question": "What is Genmab known for?",
            "answer": "Genmab is known for its development of innovative antibody therapeutics for cancer treatment."
        },
        {
            "question": "Who is the CEO of Genmab?",
            "answer": "Jan van de Winkel is the CEO of Genmab A/S."
        },
        {
            "question": "Where is Genmab headquartered?",
            "answer": "Genmab is headquartered in Copenhagen, Denmark."
        },
        {
            "question": "What are Genmab's main products?",
            "answer": "Genmab's main products include Darzalex, Teprotumumab, and various DuoBody therapeutics."
        },
        {
            "question": "When was Genmab founded?",
            "answer": "Genmab was founded in 1999."
        }
    ],
    "competitors": [
        "REGN",
        "AMGN",
        "MRNA"
    ],
    "related_stocks": [
        "ABBV",
        "BMY",
        "JNJ",
        "GILD"
    ]
}